Scientific rationale for developing potent RBD-based vaccines targeting COVID-19.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
28 Oct 2021
28 Oct 2021
Historique:
received:
10
05
2021
accepted:
01
10
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Vaccination of the global population against COVID-19 is a great scientific, logistical, and moral challenge. Despite the rapid development and authorization of several full-length Spike (S) protein vaccines, the global demand outweighs the current supply and there is a need for safe, potent, high-volume, affordable vaccines that can fill this gap, especially in low- and middle-income countries. Whether SARS-CoV-2 S-protein receptor-binding domain (RBD)-based vaccines could fill this gap has been debated, especially with regards to its suitability to protect against emerging viral variants of concern. Given a predominance for elicitation of neutralizing antibodies (nAbs) that target RBD following natural infection or vaccination, a key biomarker of protection, there is merit for selection of RBD as a sole vaccine immunogen. With its high-yielding production and manufacturing potential, RBD-based vaccines offer an abundance of temperature-stable doses at an affordable cost. In addition, as the RBD preferentially focuses the immune response to potent and recently recognized cross-protective determinants, this domain may be central to the development of future pan-sarbecovirus vaccines. In this study, we review the data supporting the non-inferiority of RBD as a vaccine immunogen compared to full-length S-protein vaccines with respect to humoral and cellular immune responses against both the prototype pandemic SARS-CoV-2 isolate and emerging variants of concern.
Identifiants
pubmed: 34711846
doi: 10.1038/s41541-021-00393-6
pii: 10.1038/s41541-021-00393-6
pmc: PMC8553742
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
128Informations de copyright
© 2021. The Author(s).
Références
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Lancet Infect Dis. 2021 Jul;21(7):950-961
pubmed: 33705727
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Cell Res. 2021 Sep;31(9):1011-1023
pubmed: 34267349
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Cell Discov. 2021 Aug 18;7(1):71
pubmed: 34408130
Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):
pubmed: 34493582
Biochim Biophys Acta Gen Subj. 2021 Jun;1865(6):129893
pubmed: 33731300
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
Clin Microbiol Infect. 2021 Jul 10;:
pubmed: 34256141
Science. 2021 Aug 13;373(6556):
pubmed: 34210892
Lancet Infect Dis. 2021 Aug;21(8):1107-1119
pubmed: 33773111
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
Science. 2021 Aug 6;373(6555):648-654
pubmed: 34210893
N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
Vaccine. 2020 Feb 24;38(9):2250-2257
pubmed: 31767462
Hum Vaccin Immunother. 2021 Aug 3;17(8):2356-2366
pubmed: 33847226
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Cell. 2020 Nov 25;183(5):1367-1382.e17
pubmed: 33160446
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Trials. 2020 Oct 15;21(1):853
pubmed: 33059771
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
Sci Adv. 2021 Mar 19;7(12):
pubmed: 33608249
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
J Biol Chem. 2021 Jan-Jun;296:100025
pubmed: 33154165
Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):
pubmed: 34470866
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Sci Adv. 2021 Mar 19;7(12):
pubmed: 33741598
Science. 2021 Feb 12;371(6530):735-741
pubmed: 33436524
N Engl J Med. 2021 Jun 3;384(22):2161-2163
pubmed: 33826816
mBio. 2021 Mar 2;12(2):
pubmed: 33653891
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
Cell Host Microbe. 2021 May 12;29(5):806-818.e6
pubmed: 33894127
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Sci Transl Med. 2021 Aug 18;13(607):
pubmed: 34315826
Lancet Infect Dis. 2021 Jun;21(6):803-812
pubmed: 33548194
Nature. 2020 Oct;586(7830):572-577
pubmed: 32726802
Nature. 2021 Jun;594(7862):253-258
pubmed: 33873199
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
Vaccines (Basel). 2021 Jul 09;9(7):
pubmed: 34358183
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):
pubmed: 34417349
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Cell. 2021 Jul 22;184(15):3936-3948.e10
pubmed: 34192529
Nature. 2021 Sep;597(7874):97-102
pubmed: 34261126
Nature. 2021 Sep;597(7874):103-108
pubmed: 34280951
Cell. 2020 Aug 6;182(3):722-733.e11
pubmed: 32645327
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Nat Med. 2021 Jun;27(6):1062-1070
pubmed: 33888900
N Engl J Med. 2021 Sep 23;385(13):1172-1183
pubmed: 34192426
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Front Immunol. 2021 Feb 26;12:637654
pubmed: 33732258
Science. 2020 Nov 20;370(6519):950-957
pubmed: 32972994
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Lancet Reg Health Am. 2021 Dec;4:100079
pubmed: 34541571
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Lancet Microbe. 2021 Jul;2(7):e285
pubmed: 33870240
Cell Mol Immunol. 2021 Mar;18(3):749-751
pubmed: 33580169
Immunity. 2020 Dec 15;53(6):1315-1330.e9
pubmed: 33275896
Cell Res. 2020 Oct;30(10):932-935
pubmed: 32759966
Sci Transl Med. 2021 Jun 30;13(600):
pubmed: 34103407
ACS Nano. 2021 Feb 23;15(2):2738-2752
pubmed: 33464829
Appl Microbiol Biotechnol. 2021 May;105(10):4153-4165
pubmed: 33959781
Adv Mater. 2020 Dec;32(50):e2005637
pubmed: 33111375
Structure. 2021 Jul 1;29(7):655-663.e4
pubmed: 34111408
J Clin Microbiol. 2021 Sep 20;59(10):e0052721
pubmed: 34288726
MMWR Morb Mortal Wkly Rep. 2021 Aug 06;70(31):1059-1062
pubmed: 34351882
Nat Commun. 2021 Jan 22;12(1):542
pubmed: 33483491
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
ACS Infect Dis. 2021 Aug 13;7(8):2546-2564
pubmed: 34260218
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
N Engl J Med. 2021 May 20;384(20):1899-1909
pubmed: 33951374
N Engl J Med. 2021 Mar 17;384(15):1468-1470
pubmed: 33730471
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Nature. 2021 Aug;596(7871):268-272
pubmed: 34107529
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
Cell. 2021 Oct 14;184(21):5432-5447.e16
pubmed: 34619077
ACS Nano. 2021 Jun 22;15(6):9627-9637
pubmed: 33480671
Science. 2021 Jun 18;372(6548):1336-1341
pubmed: 34006597
Vaccines (Basel). 2021 Apr 16;9(4):
pubmed: 33923573
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Signal Transduct Target Ther. 2021 Jul 15;6(1):271
pubmed: 34267185
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Science. 2021 Mar 12;371(6534):1139-1142
pubmed: 33536258
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
Lancet Respir Med. 2021 Apr;9(4):333-335
pubmed: 33524316
Cell. 2020 Sep 3;182(5):1271-1283.e16
pubmed: 32795413